T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$1.82B |
| 2 |
Sea Limited
SE
|
+$1.38B |
| 3 |
Cisco
CSCO
|
+$1.16B |
| 4 |
Netflix
NFLX
|
+$1.14B |
| 5 |
Ingersoll Rand
IR
|
+$1.03B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$3.54B |
| 2 |
Amazon
AMZN
|
+$1.75B |
| 3 |
Amphenol
APH
|
+$1.65B |
| 4 |
KLA
KLAC
|
+$1.5B |
| 5 |
Xcel Energy
XEL
|
+$1.38B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.6% |
| 2 | Financials | 11.17% |
| 3 | Healthcare | 11.1% |
| 4 | Communication Services | 10.25% |
| 5 | Consumer Discretionary | 10.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
701
Oric Pharmaceuticals
ORIC
$1.25B
| $68.3M | 0.01% |
5,387,783
+2,092,661
| +64% | +$23.8M |
|
702
T. Rowe Price Dividend Growth ETF
TDVG
$1.41B
| $68.1M | 0.01% |
1,525,001
| – | – |
|
703
Astera Labs
ALAB
$50B
| $67.8M | 0.01% |
618,499
-545,915
| -47% | -$77.8M |
|
704
MP Materials
MP
$7.35B
| $67.3M | 0.01% |
1,393,457
-349,218
| -20% | -$20.9M |
|
705
HealthEquity
HQY
$7.91B
| $67.1M | 0.01% |
803,427
-514,292
| -39% | -$42.2M |
|
706
Celldex Therapeutics
CLDX
$2.77B
| $66.2M | 0.01% |
2,086,332
+46,627
| +2% | +$1.27M |
|
707
Occidental Petroleum
OXY
$57B
| $65.8M | 0.01% |
1,011,915
-29,292
| -3% | -$1.47M |
|
708
Arrowhead Research
ARWR
$12.1B
| $65.4M | 0.01% |
1,043,732
+204,914
| +24% | +$13M |
|
709
American Healthcare REIT
AHR
$11.1B
| $65.4M | 0.01% |
1,386,305
+384,367
| +38% | +$19.1M |
|
710
Beam Therapeutics
BEAM
$2.58B
| $64.7M | 0.01% |
2,713,230
-17,052
| -0.6% | -$473K |
|
711
Douglas Emmett
DEI
$2.06B
| $64.4M | 0.01% |
6,836,853
-36,910
| -0.5% | -$380K |
|
712
Ford
F
$57.3B
| $64.4M | 0.01% |
5,577,749
-155,939
| -3% | -$2.05M |
|
713
ESCO Technologies
ESE
$8.49B
| $64.3M | 0.01% |
228,578
+76,278
| +50% | +$19.2M |
|
714
Wave Life Sciences
WVE
$1.12B
| $63.1M | 0.01% |
8,704,550
+1,297,178
| +18% | +$16.9M |
|
715
Stoke Therapeutics
STOK
$1.82B
| $63M | 0.01% |
1,934,171
+1,561,837
| +419% | +$51.2M |
|
716
Viridian Therapeutics
VRDN
$2.13B
| $62.7M | 0.01% |
3,206,035
-233,379
| -7% | -$6.93M |
|
717
Immunome
IMNM
$2.52B
| $62.5M | 0.01% |
2,858,863
-521,377
| -15% | -$11.6M |
|
718
On Holding
ONON
$11.9B
| $62.5M | 0.01% |
1,835,806
-902,886
| -33% | -$39.4M |
|
719
Replimune Group
REPL
$814M
| $62.1M | 0.01% |
8,121,433
-140,863
| -2% | -$1.08M |
|
720
Delta Air Lines
DAL
$55.9B
| $62M | 0.01% |
932,460
-17,684
| -2% | -$1.19M |
|
721
Essential Utilities
WTRG
$11.2B
| $61.7M | 0.01% |
1,532,975
+1,296,496
| +548% | +$51M |
|
722
Iron Mountain
IRM
$38.2B
| $61.4M | 0.01% |
601,581
-5,278
| -0.9% | -$525K |
|
723
Universal Technical Institute
UTI
$2.08B
| $61.4M | 0.01% |
1,700,286
+100,752
| +6% | +$3.18M |
|
724
Fastly Inc
FSLY
$3.17B
| $61.3M | 0.01% |
2,108,776
+1,947,756
| +1,210% | +$32M |
|
725
CoStar Group
CSGP
$11.3B
| $61.2M | 0.01% |
1,517,795
+318,963
| +27% | +$16.6M |
|
Similar funds
T. Rowe Price Associates's Q1 2026 Portfolio in Review
As of Q1 2026, T. Rowe Price Associates held 3,202 positions worth $865B, down 6.7% from $927B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
T. Rowe Price Associates's Q1 2026 filing shows 115 new, 2,022 increased, 804 reduced and 71 closed positions. Its largest new stake was Cenovus Energy: 23,907,299 shares worth $634M. The largest sale was Microsoft, an estimated $3.54B.
By sector, the portfolio is most concentrated in Technology at 34% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q1 2026 buy was Cenovus Energy: 23,907,299 shares worth $634M.
- T. Rowe Price Associates added most to Advanced Micro Devices in Q1 2026, an estimated $1.82B increase.
- T. Rowe Price Associates's biggest Q1 2026 reduction was Microsoft, cutting an estimated $3.54B.
- T. Rowe Price Associates fully exited CyberArk in Q1 2026, selling an estimated $251M.
- T. Rowe Price Associates's ten largest holdings make up 34% of its $865B portfolio in Q1 2026.
- T. Rowe Price Associates opened 115 new positions and closed 71 in Q1 2026.
- T. Rowe Price Associates's portfolio value fell 6.7% quarter-over-quarter to $865B.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.